The Biomarkers Consortium’s Cancer, Inflammation & Immunity, Metabolic Disorders and Neuroscience Steering Committees are responsible for identifying and moving forward promising pre-competitive biomarkers projects for implementation by The Biomarkers Consortium, as well as overseeing each individual project under its purview.

The members of each Steering Committee represent a variety of sectors, including academia, government, industry and not-for-profit/advocacy organizations, and are led by two co-chairs representing two of the following three sectors: academia, government or industry.

See below for the membership of each Biomarkers Consortium Steering Committee:

  Cancer Steering Committee

Gary Kelloff, M.D., NIH/NCI , (Co-Chair)
Eric Rubin, M.D., Merck (Co-Chair)
Lukas Amler, Ph.D., Genentech, a member of the Roche Group
Daniel Auclair, Ph.D., The Multiple Myeloma Research Foundation
J. Carl Barrett, M.D., AstraZeneca
Donald A. Berry, Ph.D., MD Anderson Cancer Center
Anahita Bhathena, Ph.D., AbbVie
Gideon Blumenthal, M.D., FDA/CDER
Lisa Butterfield, Ph.D., Society for Immunotherapy of Cancer
Claudio Carini, M.D., Ph.D., Oxford Biodynamics
Steven Cole, NIH/NCI
Allison M. Cushman-Vokoun, M.D., Ph.D., University of Nebraska
Ajeeta Dash, Ph.D., Takeda Pharmaceuticals International, Inc.
Gregory Friberg, M.D., Amgen
Ida Grundberg, Ph.D., Olink Proteomics
Steve Gutman, M.D., Illumina
Stanley R. Hamilton, M.D., MD Anderson Cancer Center
Sean Hanlon, Ph.D., NIH/NCI
Steffan Ho, M.D., Ph.D., Pfizer
Karl Hsu, M.D., Sanofi
Mohamad Hussein, M.D., Celgene Corporation
John Jessup, M.D., Inova
Yi Jia, Ph.D., Somalogic
Ilan (Lanny) Kirsch, M.D., Adaptive Biotechnologies
Michelle Berny-Lang, Ph.D., NIH/NCI
Dirk Laurent, M.D., Bayer
Ian McCaffery, Ph.D., Janssen
Robert McCormack, Ph.D.
Helen Moore, Ph.D., NIH/NCI
Larry Nagahara, Ph.D., Johns Hopkins University
Michael O’Neal, M.D., BioClinica, Inc.
Jim Pannucci, Ph.D., Frederick National Laboratory For Cancer Research
David Parkinson, M.D., Essa Pharmaceuticals
Narges Rashidi, Ph.D., Olink Proteomics
Gregory Reaman, M.D., FDA/CDER
Ximena Restrepo, M.S., CPHP, Society for Immunotherapy of Cancer
Henry Rodriguez, Ph.D., NIH/NCI
Marijana Rucevic, Ph.D., Olink Proteomics
Amy Kate Sasser, Ph.D., Genmab
Houssein Abdul Sater, M.D., NIH/NCI
Andrew E. Schade, M.D., Ph.D., Eli Lilly & Company
Mitchell Schnall, M.D., Ph.D., University of Pennsylvania
Lawrence Schwartz, M.D., Columbia University
Julie Schneider, Ph.D., FDA/OC
Ellen V. Sigal, Ph.D., Friends of Cancer Research
Andrew D. Simmons, Ph.D., Clovis Oncology
Jacqueline Smith, Society for Immunotherapy of Cancer
Daniel C. Sullivan, M.D., Duke University
Nancy Valente, M.D., Genentech, a member of the Roche Group
Wolfgang Weber, M.D., Memorial Sloan Kettering
Mickey Williams, Ph.D., NIH/NCI
Kevin Yarasheski, Ph.D., C2N Diagnositcs

  Inflammation & Immunity Steering Committee

David Fox, M.D., University of Michigan (Co-Chair)
David Chang, M.D., M.P.H, F.A.C.R., AstraZeneca (Co-Chair)
Robert Benschop, Ph.D., Eli Lilly
Maria Bettinotti, Ph.D., Association for Molecular Pathology
Anita Boyapati, Ph.D., Regeneron
Carrie Brodmerkel, Ph.D., Janssen (JNJ)
Katherine Call, Ph.D., Genzyme (Sanofi)
Claudio Carini, M.D., Ph.D., Oxford Biodynamics
James Chung, M.D., Amgen
Carolyn Cuff, Ph.D., AbbVie
Mark Curran, Ph.D., Janssen (JNJ)
Sean Curtis, M.D., Merck
Sahar Dawisha, M.D., FDA/CDRH
Betty Diamond, Ph.D., Feinstein Institute
Guy Eakin, Ph.D., Arthritis Foundation
Thomas Fuerst, Ph.D., BioClinica
Kristie M. Grebe, Ph.D, AbbVie
Jennifer Hall, Ph.D., American Heart Association
Kathy Jung, Ph.D.,  NIH/NIAA
Bruce Littman, M.D., Portage Pharmaceuticals Ltd.
Bruce McManus, M.D., Ph.D., University of British Columbia
Nikolay Nikolov, M.D., FDA/CDER
Jim Pannucci, Ph.D., Frederick National Laboratory For Cancer Research
Barbara Radziszewska, Ph.D., M.P.H., NIH/NIA
Mahboob Rahman, M.D., Ph.D., Novartis
Koustubh Ranade, Ph.D., Medimmune (AstraZeneca)
Narges Rashidi, Ph.D., OLINK
John Reveille, M.D., University of Texas Health Science Center (Houston)
Lisa Rider, M.D., NIH/NIEHS
Dan Rotrosen, M.D., NIH/NIAID
Jane Salmon, M.D., Hospital for Special Surgery
Linda Sandell, Ph.D., Washington University, St. Louis (OARSI).
Susana A. Serrate-Sztein, M.D., NIH/NIAMS
Glennda Smithson, Ph.D., Takeda
Lisa M. Spain, Ph.D., NIH/ NIDDK
Giorgio Trinchieri, M.D., NIH/NINDS
Ursula Utz, MBA, Ph.D., NIH/ NINDS
Stephen Williams, M.D., Ph.D., SomaLogic
James Witter, M.D., Ph.D., NIH/NIAMSD
Kevin Yarasheski, Ph.D., C2N Diagnositcs

  Metabolic Disorders Steering Committee

Myrlene Staten, M.D., NIH/NIDDK (Co-Chair)
Roberto Calle, M.D., Pfizer (Co-Chair)
Cynthia Arbeeny, Ph.D., Sanofi
Poulabi Banerjee, Ph.D., Regeneron
Carlos Blanco, M.D., Ph.D., NIH/NIDA
Anita Boyapati, Ph.D., Regeneron
Bidisha Dasgupta, Ph.D., JNJ
Samuel Engel, M.D., Merck
Klaus Engelke, Ph.D., BioClinica
David Fryburg, M.D., ROI BioPharma Consulting
Saurabh Gupta, Ph.D., Takeda
Jennifer Hall, M.D., The American Heart Association
Aaron Hinken, Ph,.D., GSK
Boaz Hirschberg, M.D., AstraZeneca
Claude Hughes, M.D., Ph.D., Quintiles
Teresa L. Jones, M.D., NIH/ NIDDK
Lyndon Joseph, Ph.D., NIH/NIA
Helina Kassahun, M.D., Amgen
Keith Kaufman, M.D., Merck
Young S. Kim, Ph.D., NIH/NCI
Paul Kimmel, M.D., NIH/NIDDK
Olof Dahlqvist Leinhard, Ph.D., AMRA Medical
Saul Malozowski, M.D., Ph.D., MBA, NIH/NIDDK
Rong Mao, M.D., The Association for Molecular Pathology
Frank Martin, Ph.D., JDRF
Allison McElvaine, Ph.D., ADA
Linda Morrow, M.D., ProSciento, Inc.
David Neil, M.D., GSK
John W. Newcomer, M.D., Florida Atlantic University
Maria-Magdalena Petru, M.D., Ortho Clinical Diagnostics
Bruce S. Schneider, M.D., FDA/CBER
Sudha Shankar, M.D., NGM Bio
Robert Sherwin, M.D., Yale University
Michelle Slimko, M.P.H., R.D., National Dairy Council
Pothur Srinivas, Ph.D., NIH/NHLBI
Elizabeth Stafford, Ph.D., FDA/CDRH
Moises Torres-Gonzalez, Ph.D., Dairy Research Institute
Robert Umek, Ph. D., MesoScale Diagnostics
David R. Vera, Ph.D., University of California, San Diego
Jessica Williams, J.D. SomaLogic
Kevin Yarasheski, Ph.D., C2N Diagnostics

  Neuroscience Steering Committee

Linda Brady, Ph.D., NIH/NIMH (Co-Chair)
Hartmuth Kolb, Ph.D., J&J (Co-Chair)
William Potter, M.D., Ph.D., NIH/NIMH (Co-Chair Emeritus)
Daniel Barboriak, M.D., RSNA
Wade Berrettini, M.D., Ph.D., UPenn
Silvana Borges, M.D., FDA
Brian Campbell, Ph.D., Ryan Institute Neuroscience
Claudio Carini, M.D. Ph.D., Oxford Biodynamics
Maria Carrillo, Ph.D., Alzheimer's Association
Caroline Cohen, Ph.D., Sanofi
Susan Croll, Ph.D., Regeneron
Howard Fillit, M.D., ADDF
Thomas P. Finn, Ph.D., FDA/CBER
Bernard Fischer, M.D., FDA/CDER
Mark Forman, M.D., Ph.D., Merck
Mark Frasier, Ph.D., Michael J. Fox Foundation
Lauren Friedman, Ph.D., ADDF
Danielle Graham, Ph.D., Biogen Idec
Ida Grundberg PhD, Olink Proteomics
Jon Heimer, Olink Proteomics
James Hendrix, Ph.D., Alzheimer’s Association
M. Katherine Jung, Ph.D., NIH/NIAAA
Walter J. Koroshetz, M.D., NIH/NINDS
Frank Lebeda, Ph.D., US Military
Eliezer Masliah, Ph.D., NIH/NIA
Bradley Miller, M.D., Ph.D., Lilly
David Millis, M.D., M.B.A., Ph.D., FDA/CDER
Jose Luis Molinuevo, M.D., Ph.D., Barcelona Beta Brain Research Center
Niels Plath, Ph.D., Lundbeck
Stephane Pollentier, M.D., Boehringer-Ingelheim
Sounder Regunathan, Ph.D., NIH/NIAAA
Cristina Sampaio, M.D., Ph.D., CHDI
Steve Sands, Ph.D., Amgen
Darryl Schoepp, Ph.D., Merck & Co.
Nina Schor, Ph.D., NIH/NINDS
Howard Schulman, Ph.D., Allosteros Therapeutics
Lamya Shihabuddin, Ph.D., Sanofi
Holly Soares, Ph.D., Abbvie
Joyce Suhy, Ph.D., BioClinica
Marg Sutherland, Ph.D., NINDS
Johannes Tauscher, M.D., Takeda
Chris Turck, Ph.D., Max Planck Institute of Psychiatry
Robert Umek, Ph.D. Meso-Scale Diagnostics
Gabriel Vargas, Ph.D., Amgen
Stephen Williams, M.D., Ph.D., SomaLogic
Kevin Yarasheski, Ph.D., C2N Diagnositcs
Henrik Zetterberg, M.D., Ph.D., University of Gothenburg
 

 

Front Page: